Skip to content

May 14, 2026

ChatGPT Image May 7, 2026, 07_11_28 PM

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
M&A / Deals
Zydus to acquire Assertio in $166m deal

M&A / Deals

Zydus to acquire Assertio in $166m deal

Pharmaceutical Technology

Zydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidiary Zydus Worldwide DMCC.

Read full story

pharminent May 14, 2026 (Last updated: May 14, 2026)

Pharmaceutical Technology

Zydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidiary Zydus Worldwide DMCC.

Read full story

Post navigation

Previous: Pfizer receives EC approval for Hympavzi to treat haemophilia

Next: Regulatory round-up: A month of key FDA approvals for cancer drugs

Related Stories

M&A / Deals

Degron adds $40M to series A, supporting immunology plans for molecular glue platform

pharminent May 14, 2026

M&A / Deals

Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B

pharminent May 13, 2026

M&A / Deals

BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal

pharminent May 12, 2026

You May Have Missed

Pipeline

Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism

pharminent May 14, 2026

Regulatory

With new data, Regenxbio to seek FDA approval of Duchenne gene therapy

pharminent May 14, 2026

Policy / Pricing

Biotech leaders pitch Pazdur as next FDA chief

pharminent May 14, 2026

M&A / Deals

Degron adds $40M to series A, supporting immunology plans for molecular glue platform

pharminent May 14, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.